SlideShare a Scribd company logo
1 of 17
UNDERSTANDING OF CHEMICAL
CARCINOGENESIS:
CURRENTAND FUTURE PERSPECTIVES
Chander K Negi
Chandernegi09@gmail.com
1
TABLE OF CONTENTS
• INTRODUCTION
• CLASSIFICATION OF CHEMICAL CARCINOGENS
• MECHANISM OF ACTION
• ROLE OF OXIDATIVE STRESS
• CURRENT AND FUTURE PERSPECTIVES
• REGULATORY BACKGROUND
• CONCLUSION
2
INTRODUCTION
Carcinogenesis refers to the process by which a normal
cell is transformed into a malignant cell and repeatedly
divides to become a cancer
Chemicals which initiate this process is called chemical
carcinogens
Chemicals which increase the effectiveness of
carcinogens is called co-carcinogens 3
CLASSIFICATION OF CHEMICAL CARCINOGENS
4
CARCINOGENS
NON GENOTOXICGENOTOXIC
Direct acting
Indirect
acting
Promoters Cytotoxins
Endocrine
modifiers
Peroxisome
proliferators
Immune
suppressors
S. M. Cohen, L. L. Arnold, Chemical carcinogenesis, Toxicol Sci 120 Suppl 1. (2011) S76-92
MECHANISM OF ACTION
5
Carcinogen
Inactive productReactive intermediate
DNA adduct DNA mutation Cancer
Error free DNA
DNA repair
Phase1 and phase 2
metabolism
P. Joseph, Chemical Carcinogenesis; Recent Advances and the Future Directions, Aust- Asian J Cancer. 4(4) (2005) 7
STAGES OF CARCINOGENESIS
6
Chemicals
Normal cells
Initiated cells
INITIATION PROMOTION
DNA repair Cellular
proliferation
PROGRESSION
CANCER
MULTISTEP PROCESS
L. A. Loeb, Harris C C, Advances in chemical carcinogenesis: a historical review and prospective, Cancer Res.
68(17) (2008) 6863-6872.
ROLE OF PROTO-ONCOGENES AND TUMOR
SUPPRESSOR GENES
Two classes of genes are mainly involved in carcinogenesis
1. Proto oncogenes
 Involved in growth and differentiation
 Activated in cancers
2. Tumor suppressor genes
 Negative regulators of growth
 Inactivated in cancers
7
ACTIVATION OF PROTO ONCOGENES
 Point mutation
 Chromosome translocation
 Gene amplification
 Ras oncogene - first activated proto-oncogene detected in a human tumor
Permanent activation/over expression lead to neoplastic
transformation
8
 Mutations of the Ras gene lower the GTPase activity of the protein .
 locks Ras in the permanently active GTP-bound form
 eventually lead to uncontrolled proliferation and transformation.
9A. Luch, Nature and nurture - lessons from chemical carcinogenesis, Nat Rev Cancer .5(2) (2005) 113-125
INACTIVATION OF TUMOR SUPPRESSOR GENE
DNA damage DNA damage
p53 activated and binds
to DNA
p53 dependent genes not
activated
Transcriptional upregulation of target
genes
p21
(CDK Inhibitor)
GADD45
(DNA repair)
Bax Mutant cells
G1 arrest
Succesful repair
Apoptosis
No cell cycle
arrest
No DNA
repair
Malignant tumour
Normal cell
DNA repair
fails
10
J. Yang, P. Duerksen-Hughes, A new approach to identifying genotoxic carcinogens: p53 induction as an indicator of genotoxic damage, Carcinogenesis. 19 (1998) 1117-1125.
OXIDATIVE STRESS IN CARCINOGENESIS
• ROS can be produced from both endogenous and exogenous sources
• Attack both purine and pyrimidine bases, as well as the deoxyribose
backbone
• Induces DNA damage which includes single or double-strand
breakage, deoxyribose modification, and DNA cross-link
• If DNA damage is not properly repaired it may result in mutation
which leads to cancer
11
CURRENT PERSPECTIVES
12
NEW
TECHNO-
LOGIES
Micro
array
DD
SSH
SAGE
Ι. IMPACT OF TECHNOLOGIES
P. Joseph, Chemical Carcinogenesis; Recent Advances and the Future Directions, Aust- Asian J Cancer. 4(4) (2005) 7
ΙΙ. BIOMARKERS
ΙΙΙ. BIOSENSORS
• Device that contains two main components including a sensing
receptor and a detector
• Improve the sensitivity and specificity of the biomarker
• Effective early detection without pain with a noninvasive technique.
13
• Carcinoembryonic antigen (CEA) - breast cancer
• Neuron specific enolase (NSE) - lung cancer
• α-fetoprotein (AFP) - liver cancer
• Prostate specific antigen (PSA) - prostate cancer
Z. Altintas, I. Tothill, Biomarkers and biosensors for the early diagnosis of lung cancer, Sensors
and Actuators B: Chemical. 188(0) (2013) 988-998
FUTURE DIRECTIONS
Development of new preclinical models for carcinogenesis
 Future challenge is to develop and validate biomarkers for non
genotoxic chemical carcinogens
Understanding chemical carcinogenesis with
Inter-individual variation
Alteration in gene expression
14
REGULATORY BACKGROUND
OECD guidelines
 451- Carcinogenecity studies
 453- Combined chronic toxicity/carcinogenecity
ICH guidelines
 S1A- Guideline on the need for carcinogenicity studies of
pharmaceuticals
 S1B- Testing for carcinogenicity of pharmaceuticals
 S1C- Dose selection for carcinogenicity studies of
pharmaceuticals
15
CONCLUSION
• Though remarkable progress has been achieved in understanding
chemical carcinogenesis, still it remain leading cause for death in
world
• Currently the development in genomics, proteomics and
informatics for identification and validation of biomarkers enable
us to determine chemical basis of carcinogenesis
• Understanding at molecular level is perhaps most important step
in developing strategies to prevent incidence of chemical
carcinogenesis 16
17

More Related Content

What's hot

MONOCLONAL ANTIBODIES
MONOCLONAL ANTIBODIESMONOCLONAL ANTIBODIES
MONOCLONAL ANTIBODIES
Umair hanif
 
Subacute toxicity
Subacute toxicitySubacute toxicity
Subacute toxicity
vaniarlekar
 

What's hot (20)

MONOCLONAL ANTIBODIES
MONOCLONAL ANTIBODIESMONOCLONAL ANTIBODIES
MONOCLONAL ANTIBODIES
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
 
Immunopharmacology
ImmunopharmacologyImmunopharmacology
Immunopharmacology
 
Genotoxicity studies
Genotoxicity studiesGenotoxicity studies
Genotoxicity studies
 
Genotoxicity studies
Genotoxicity studiesGenotoxicity studies
Genotoxicity studies
 
Biosimilars
Biosimilars Biosimilars
Biosimilars
 
Principles & types of bioassay
Principles & types of bioassayPrinciples & types of bioassay
Principles & types of bioassay
 
immuno stimulants
immuno stimulants immuno stimulants
immuno stimulants
 
Cancer chemotherapy
Cancer  chemotherapyCancer  chemotherapy
Cancer chemotherapy
 
Immunostimulants & immunosuppressants
Immunostimulants & immunosuppressantsImmunostimulants & immunosuppressants
Immunostimulants & immunosuppressants
 
Principles of toxicology
Principles of toxicologyPrinciples of toxicology
Principles of toxicology
 
Subacute toxicity
Subacute toxicitySubacute toxicity
Subacute toxicity
 
Carcinogenicity testing
Carcinogenicity testingCarcinogenicity testing
Carcinogenicity testing
 
Antiviral drugs
Antiviral drugsAntiviral drugs
Antiviral drugs
 
Acute and chronic toxicity studies in animals
Acute and chronic toxicity studies in animalsAcute and chronic toxicity studies in animals
Acute and chronic toxicity studies in animals
 
Screening methods for Teratogenicity
Screening methods for TeratogenicityScreening methods for Teratogenicity
Screening methods for Teratogenicity
 
Anticancer drugs 3 antimetabolites
Anticancer drugs 3 antimetabolitesAnticancer drugs 3 antimetabolites
Anticancer drugs 3 antimetabolites
 
immunostimulants
immunostimulantsimmunostimulants
immunostimulants
 
Principles of drug discovery
Principles of drug discoveryPrinciples of drug discovery
Principles of drug discovery
 
Immunomodulators
ImmunomodulatorsImmunomodulators
Immunomodulators
 

Viewers also liked

Carcinogenesis
CarcinogenesisCarcinogenesis
Carcinogenesis
Ibnu Alias
 
Carcinogenesis
CarcinogenesisCarcinogenesis
Carcinogenesis
Ejaz Waris
 
3. carcinogenesis dr. sinhasan, mdzah
3. carcinogenesis  dr. sinhasan, mdzah3. carcinogenesis  dr. sinhasan, mdzah
3. carcinogenesis dr. sinhasan, mdzah
kciapm
 
Biochemistry of aging
Biochemistry of agingBiochemistry of aging
Biochemistry of aging
Shanzay Malik
 

Viewers also liked (20)

Carcinogenesis , invasion & metastasis
Carcinogenesis , invasion & metastasis Carcinogenesis , invasion & metastasis
Carcinogenesis , invasion & metastasis
 
Carcinogenesis
CarcinogenesisCarcinogenesis
Carcinogenesis
 
Carcinogenesis
CarcinogenesisCarcinogenesis
Carcinogenesis
 
carcinogenesis-
carcinogenesis-carcinogenesis-
carcinogenesis-
 
Neoplasia 4
Neoplasia 4Neoplasia 4
Neoplasia 4
 
ASTHMA
ASTHMAASTHMA
ASTHMA
 
Carcinogenesis(penfriend841)
Carcinogenesis(penfriend841)Carcinogenesis(penfriend841)
Carcinogenesis(penfriend841)
 
KANDAKUMAR S (KK) Molecular Oncology Lab (MOL) seminar
KANDAKUMAR S (KK) Molecular Oncology Lab (MOL) seminarKANDAKUMAR S (KK) Molecular Oncology Lab (MOL) seminar
KANDAKUMAR S (KK) Molecular Oncology Lab (MOL) seminar
 
Airway remodeling in asthma
Airway remodeling in asthmaAirway remodeling in asthma
Airway remodeling in asthma
 
HTA training - Dr Roisin Adams - March 27th 2016
HTA training - Dr Roisin Adams - March 27th 2016HTA training - Dr Roisin Adams - March 27th 2016
HTA training - Dr Roisin Adams - March 27th 2016
 
Neoplasia
NeoplasiaNeoplasia
Neoplasia
 
Importance of guidelines in regulatory toxicity testing
Importance of guidelines in regulatory toxicity testingImportance of guidelines in regulatory toxicity testing
Importance of guidelines in regulatory toxicity testing
 
Carcinogénesis
CarcinogénesisCarcinogénesis
Carcinogénesis
 
Pharmacoeconomics (Basics for MD Pharmacology)
Pharmacoeconomics (Basics for MD Pharmacology)Pharmacoeconomics (Basics for MD Pharmacology)
Pharmacoeconomics (Basics for MD Pharmacology)
 
3. carcinogenesis dr. sinhasan, mdzah
3. carcinogenesis  dr. sinhasan, mdzah3. carcinogenesis  dr. sinhasan, mdzah
3. carcinogenesis dr. sinhasan, mdzah
 
Hepatotoxicity
HepatotoxicityHepatotoxicity
Hepatotoxicity
 
2. benign vs malignant dr. sinhasan, mdzah
2. benign vs malignant dr. sinhasan, mdzah2. benign vs malignant dr. sinhasan, mdzah
2. benign vs malignant dr. sinhasan, mdzah
 
Carcinogenesis Generalidades
Carcinogenesis GeneralidadesCarcinogenesis Generalidades
Carcinogenesis Generalidades
 
Biochemistry of aging
Biochemistry of agingBiochemistry of aging
Biochemistry of aging
 
Nicnas carcinogenesis8copy
Nicnas carcinogenesis8copyNicnas carcinogenesis8copy
Nicnas carcinogenesis8copy
 

Similar to Carcinogenesis

High Sensitivity Detection of Tumor Gene Mutations-v3
High Sensitivity Detection of Tumor Gene Mutations-v3High Sensitivity Detection of Tumor Gene Mutations-v3
High Sensitivity Detection of Tumor Gene Mutations-v3
Michael Powell
 
Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...
Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...
Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...
bigdatabm
 
MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...
MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...
MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...
European School of Oncology
 
New Trends in the Management of Metastatic Prostate Cancer
New Trends in the Management of Metastatic Prostate CancerNew Trends in the Management of Metastatic Prostate Cancer
New Trends in the Management of Metastatic Prostate Cancer
flasco_org
 
Provenge (sipuleucel t)
Provenge (sipuleucel t)Provenge (sipuleucel t)
Provenge (sipuleucel t)
Vinblast
 
Provenge (Sipuleucel T)
Provenge (Sipuleucel T)Provenge (Sipuleucel T)
Provenge (Sipuleucel T)
Cytokinine
 
Nuove strategie terapeutiche per il trattamento del cancro alla prostata refr...
Nuove strategie terapeutiche per il trattamento del cancro alla prostata refr...Nuove strategie terapeutiche per il trattamento del cancro alla prostata refr...
Nuove strategie terapeutiche per il trattamento del cancro alla prostata refr...
Merqurio
 

Similar to Carcinogenesis (20)

Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Impli...
Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Impli...Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Impli...
Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Impli...
 
Choueiri nivo inrcc-009_presentation@asco2015
Choueiri nivo inrcc-009_presentation@asco2015Choueiri nivo inrcc-009_presentation@asco2015
Choueiri nivo inrcc-009_presentation@asco2015
 
Pharmacogenomics
PharmacogenomicsPharmacogenomics
Pharmacogenomics
 
Proteogenomic analysis of human colon cancer reveals new therapeutic opportun...
Proteogenomic analysis of human colon cancer reveals new therapeutic opportun...Proteogenomic analysis of human colon cancer reveals new therapeutic opportun...
Proteogenomic analysis of human colon cancer reveals new therapeutic opportun...
 
High Sensitivity Detection of Tumor Gene Mutations-v3
High Sensitivity Detection of Tumor Gene Mutations-v3High Sensitivity Detection of Tumor Gene Mutations-v3
High Sensitivity Detection of Tumor Gene Mutations-v3
 
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MD
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MDTargeted Therapy for Uveal Melanoma - Richard Carvajal, MD
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MD
 
Osp2 brennan SGC
Osp2 brennan SGCOsp2 brennan SGC
Osp2 brennan SGC
 
Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...
Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...
Пятницкий М.А. Подбор персонализированной противоопухолевой терапии путем сис...
 
5943408.ppt
5943408.ppt5943408.ppt
5943408.ppt
 
MDC Connects: Use of pre-clinical models to deliver proof of concept efficacy
MDC Connects: Use of pre-clinical models to deliver proof of concept efficacyMDC Connects: Use of pre-clinical models to deliver proof of concept efficacy
MDC Connects: Use of pre-clinical models to deliver proof of concept efficacy
 
MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...
MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...
MCO 2011 - Slide 33 - C. Svedman - Spotlight session - Criteria to evaluate g...
 
Biomarker ppts of cnu
Biomarker ppts of cnuBiomarker ppts of cnu
Biomarker ppts of cnu
 
New Trends in the Management of Metastatic Prostate Cancer
New Trends in the Management of Metastatic Prostate CancerNew Trends in the Management of Metastatic Prostate Cancer
New Trends in the Management of Metastatic Prostate Cancer
 
Prostate 101
Prostate 101Prostate 101
Prostate 101
 
CHEMOTHERAPY IN CANCERS
CHEMOTHERAPY IN CANCERSCHEMOTHERAPY IN CANCERS
CHEMOTHERAPY IN CANCERS
 
Molecular Profiling of Cholangiocarcinoma - Milind Javle, MD
Molecular Profiling of Cholangiocarcinoma - Milind Javle, MDMolecular Profiling of Cholangiocarcinoma - Milind Javle, MD
Molecular Profiling of Cholangiocarcinoma - Milind Javle, MD
 
Provenge (sipuleucel t)
Provenge (sipuleucel t)Provenge (sipuleucel t)
Provenge (sipuleucel t)
 
Triple Negative Breast Cancer
Triple Negative Breast CancerTriple Negative Breast Cancer
Triple Negative Breast Cancer
 
Provenge (Sipuleucel T)
Provenge (Sipuleucel T)Provenge (Sipuleucel T)
Provenge (Sipuleucel T)
 
Nuove strategie terapeutiche per il trattamento del cancro alla prostata refr...
Nuove strategie terapeutiche per il trattamento del cancro alla prostata refr...Nuove strategie terapeutiche per il trattamento del cancro alla prostata refr...
Nuove strategie terapeutiche per il trattamento del cancro alla prostata refr...
 

Recently uploaded

Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
kauryashika82
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
PECB
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
ciinovamais
 

Recently uploaded (20)

Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot Graph
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Asian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptxAsian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptx
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SD
 

Carcinogenesis

  • 1. UNDERSTANDING OF CHEMICAL CARCINOGENESIS: CURRENTAND FUTURE PERSPECTIVES Chander K Negi Chandernegi09@gmail.com 1
  • 2. TABLE OF CONTENTS • INTRODUCTION • CLASSIFICATION OF CHEMICAL CARCINOGENS • MECHANISM OF ACTION • ROLE OF OXIDATIVE STRESS • CURRENT AND FUTURE PERSPECTIVES • REGULATORY BACKGROUND • CONCLUSION 2
  • 3. INTRODUCTION Carcinogenesis refers to the process by which a normal cell is transformed into a malignant cell and repeatedly divides to become a cancer Chemicals which initiate this process is called chemical carcinogens Chemicals which increase the effectiveness of carcinogens is called co-carcinogens 3
  • 4. CLASSIFICATION OF CHEMICAL CARCINOGENS 4 CARCINOGENS NON GENOTOXICGENOTOXIC Direct acting Indirect acting Promoters Cytotoxins Endocrine modifiers Peroxisome proliferators Immune suppressors S. M. Cohen, L. L. Arnold, Chemical carcinogenesis, Toxicol Sci 120 Suppl 1. (2011) S76-92
  • 5. MECHANISM OF ACTION 5 Carcinogen Inactive productReactive intermediate DNA adduct DNA mutation Cancer Error free DNA DNA repair Phase1 and phase 2 metabolism P. Joseph, Chemical Carcinogenesis; Recent Advances and the Future Directions, Aust- Asian J Cancer. 4(4) (2005) 7
  • 6. STAGES OF CARCINOGENESIS 6 Chemicals Normal cells Initiated cells INITIATION PROMOTION DNA repair Cellular proliferation PROGRESSION CANCER MULTISTEP PROCESS L. A. Loeb, Harris C C, Advances in chemical carcinogenesis: a historical review and prospective, Cancer Res. 68(17) (2008) 6863-6872.
  • 7. ROLE OF PROTO-ONCOGENES AND TUMOR SUPPRESSOR GENES Two classes of genes are mainly involved in carcinogenesis 1. Proto oncogenes  Involved in growth and differentiation  Activated in cancers 2. Tumor suppressor genes  Negative regulators of growth  Inactivated in cancers 7
  • 8. ACTIVATION OF PROTO ONCOGENES  Point mutation  Chromosome translocation  Gene amplification  Ras oncogene - first activated proto-oncogene detected in a human tumor Permanent activation/over expression lead to neoplastic transformation 8
  • 9.  Mutations of the Ras gene lower the GTPase activity of the protein .  locks Ras in the permanently active GTP-bound form  eventually lead to uncontrolled proliferation and transformation. 9A. Luch, Nature and nurture - lessons from chemical carcinogenesis, Nat Rev Cancer .5(2) (2005) 113-125
  • 10. INACTIVATION OF TUMOR SUPPRESSOR GENE DNA damage DNA damage p53 activated and binds to DNA p53 dependent genes not activated Transcriptional upregulation of target genes p21 (CDK Inhibitor) GADD45 (DNA repair) Bax Mutant cells G1 arrest Succesful repair Apoptosis No cell cycle arrest No DNA repair Malignant tumour Normal cell DNA repair fails 10 J. Yang, P. Duerksen-Hughes, A new approach to identifying genotoxic carcinogens: p53 induction as an indicator of genotoxic damage, Carcinogenesis. 19 (1998) 1117-1125.
  • 11. OXIDATIVE STRESS IN CARCINOGENESIS • ROS can be produced from both endogenous and exogenous sources • Attack both purine and pyrimidine bases, as well as the deoxyribose backbone • Induces DNA damage which includes single or double-strand breakage, deoxyribose modification, and DNA cross-link • If DNA damage is not properly repaired it may result in mutation which leads to cancer 11
  • 12. CURRENT PERSPECTIVES 12 NEW TECHNO- LOGIES Micro array DD SSH SAGE Ι. IMPACT OF TECHNOLOGIES P. Joseph, Chemical Carcinogenesis; Recent Advances and the Future Directions, Aust- Asian J Cancer. 4(4) (2005) 7
  • 13. ΙΙ. BIOMARKERS ΙΙΙ. BIOSENSORS • Device that contains two main components including a sensing receptor and a detector • Improve the sensitivity and specificity of the biomarker • Effective early detection without pain with a noninvasive technique. 13 • Carcinoembryonic antigen (CEA) - breast cancer • Neuron specific enolase (NSE) - lung cancer • α-fetoprotein (AFP) - liver cancer • Prostate specific antigen (PSA) - prostate cancer Z. Altintas, I. Tothill, Biomarkers and biosensors for the early diagnosis of lung cancer, Sensors and Actuators B: Chemical. 188(0) (2013) 988-998
  • 14. FUTURE DIRECTIONS Development of new preclinical models for carcinogenesis  Future challenge is to develop and validate biomarkers for non genotoxic chemical carcinogens Understanding chemical carcinogenesis with Inter-individual variation Alteration in gene expression 14
  • 15. REGULATORY BACKGROUND OECD guidelines  451- Carcinogenecity studies  453- Combined chronic toxicity/carcinogenecity ICH guidelines  S1A- Guideline on the need for carcinogenicity studies of pharmaceuticals  S1B- Testing for carcinogenicity of pharmaceuticals  S1C- Dose selection for carcinogenicity studies of pharmaceuticals 15
  • 16. CONCLUSION • Though remarkable progress has been achieved in understanding chemical carcinogenesis, still it remain leading cause for death in world • Currently the development in genomics, proteomics and informatics for identification and validation of biomarkers enable us to determine chemical basis of carcinogenesis • Understanding at molecular level is perhaps most important step in developing strategies to prevent incidence of chemical carcinogenesis 16
  • 17. 17